Newsletter
Donate
  • Will the new COVID-19 antiviral be accessible?

    Will the new COVID-19 antiviral be accessible?

    Melanie Marich

    In June, the Food and Drug Administration approved the drug Xocova (ensitrelvir) as the very first post-exposure prophylaxis for Sars-CoV-2, and if taken within 72 hours, it could stop a SARS-CoV-2 infection in its tracks. The drug is also being studied as a potential Long COVID treatment and even maybe as a preventative. But how accessible will this drug be? Read more…

Recent articles

Get the latest Long COVID news and commentary

Sign up for our free newsletter, delivered every Tuesday! Receive our latest stories, research updates, COVID-19 trends, and more.

Processing…
Success! You're on the list.

Check out our weekly podcast, Still Here

SpotifySpotifyApple PodcastsApple PodcastsPocketCastsPocketCastsiHeartRadioiHeartRadioRSSRSS

Trending

FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?Miles W. Griffis
The U.K.’s plan for ME has failed us. Members of parliament must step up.The U.K.’s plan for ME has failed us. Members of parliament must step up.Nick Benton
We must free Long COVID and the people living with it from the mind-body trapWe must free Long COVID and the people living with it from the mind-body trapTodd Davenport
I worked in homeless services for years. It didn’t help me find accessible housing when I got Long COVID.I worked in homeless services for years. It didn’t help me find accessible housing when I got Long COVID.Rachel Litchman
National COVID-19 trends, June 23National COVID-19 trends, June 23Betsy Ladyzhets

Policy & Advocacy

Science

Covid-19

Health

Commentary